Wall Street Zen Upgrades Myriad Genetics (NASDAQ:MYGN) to "Hold"

Key Points

• Wall Street Zen upgraded Myriad Genetics from “sell” to “hold.” Analyst sentiment overall is also “hold,” with a consensus price target of $5.55.
• Myriad reported quarterly revenue of $202.7 million and a loss of $0.11 per share, beating analysts’ estimates; it also raised the midpoint of its FY2026 revenue outlook to $780 million–$790 million.
• The company agreed to sell its Prenatal Health business for $210 million and is investigating unauthorized access to its IT systems, adding financial and cybersecurity considerations for investors.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday, Wall Street Zen reports.

MYGN has been the topic of several other reports. Leerink Partners lifted their target price on Myriad Genetics from $5.00 to $8.00 and gave the stock a "market perform" rating in a report on Thursday. UBS Group initiated coverage on Myriad Genetics in a report on Wednesday, September 9th. They issued a "neutral" rating and a $3.60 price objective for the company. Wells Fargo & Company set a $4.50 price target on Myriad Genetics in a report on Tuesday, October 20th. Stephens lowered their price target on Myriad Genetics from $5.00 to $3.00 and set an "equal weight" rating on the stock in a report on Tuesday, August 18th. Finally, Piper Sandler raised Myriad Genetics from an "underweight" rating to a "neutral" rating and set a $5.00 target price for the company in a report on Tuesday, October 20th. One equities research analyst has rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $5.55.

Myriad Genetics Trading Down 5.9%

MYGN opened at $5.92 on Friday. Myriad Genetics has a one year low of $2.74 and a one year high of $8.09. The stock has a market capitalization of $566.25 million, a PE ratio of -4.35 and a beta of 1.62. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.21. The business's 50 day moving average price is $4.50 and its 200 day moving average price is $4.62.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.09. Myriad Genetics had a negative net margin of 13.96% and a negative return on equity of 16.09%. The company had revenue of $202.70 million for the quarter, compared to the consensus estimate of $191.33 million. As a group, equities research analysts expect that Myriad Genetics will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Myriad Genetics

Several large investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new position in Myriad Genetics in the 2nd quarter worth about $62,184,000. Bank of America Corp DE purchased a new position in shares of Myriad Genetics during the 2nd quarter worth $5,150,000. Bank of New York Mellon Corp purchased a new stake in Myriad Genetics in the second quarter valued at $1,930,000. Orbimed Advisors LLC acquired a new stake in Myriad Genetics in the first quarter valued at $562,500,000. Finally, Man Group plc acquired a new position in Myriad Genetics in the second quarter valued at $5,189,000. Hedge funds and other institutional investors own 99.02% of the company's stock.

Key Stories Impacting Myriad Genetics

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Myriad reported Q3 revenue of $202.7 million, above analysts’ $191.33 million estimate, and a loss of $0.11 per share—narrower than the expected $0.20 loss. The company also raised the midpoint of its FY2026 revenue outlook to a range of $780 million–$790 million. Article: Myriad Genetics Raises FY26 Revenue Outlook Midpoint
• Positive Sentiment: TD Cowen raised its price target to $6.75 from $4.50, while retaining a Hold rating; Leerink Partners raised its target to $8 from $5, with a Market Perform rating. Higher targets suggest improved expectations, though neither firm upgraded its rating. Article: TD Cowen price target
• Neutral Sentiment: Myriad agreed to sell its Prenatal Health business for $210 million. The proceeds could support the company’s finances and focus, but the divestiture also changes its revenue base; the outlook is presented following the sale. Article: Myriad outlines 2026 outlook following divestiture
• Negative Sentiment: The company said it detected unauthorized access to its information technology systems on November 2 and is investigating whether data was accessed. Potential exposure of sensitive information or disruption creates uncertainty and could be contributing to investor concern. Article: Myriad reports cybersecurity incident

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostics company that develops and provides genetic tests and related services to help healthcare providers assess disease risk, guide treatment decisions and support patient care. The company's testing portfolio spans hereditary cancer, precision oncology, women's health, mental health and other clinical applications.

Its products include hereditary cancer risk tests such as MyRisk and BRACAnalysis, which evaluate inherited genetic variants associated with cancers including breast and ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.